Overdose of Tirzepatide: What Happens and What to Do

What the SmPC and regulatory guidance actually say about taking too much

The Mounjaro Summary of Product Characteristics, accessible via the eMC, states plainly that in the event of overdose, treatment should consist of supportive measures appropriate to the person's symptoms. No specific antidote exists. That framing reflects where the clinical evidence stands: tirzepatide trials (including the large SURMOUNT programme, which recruited thousands of adults) captured adverse events at licensed doses, not at overdose levels, so extrapolated risk is based on mechanism rather than a body of overdose case data.

What the mechanism tells us is important. Tirzepatide acts on two gut-hormone receptors (GIP and GLP-1) simultaneously, slowing gastric emptying and reducing appetite. At supra-therapeutic levels, those same actions intensify: gastric motility slows further, and the insulin-stimulating effect of GLP-1 agonism can drive blood sugar lower than intended, a particular concern for anyone who also takes other glucose-lowering medicines. The heart-rate elevation sometimes seen at normal doses may also be amplified.

If you are uncertain whether you have injected a full extra dose or just a partial one, treat it as a potential overdose and seek advice. The NHS 111 service can triage urgency quickly. For severe symptoms (sustained vomiting, chest discomfort, or collapse) go directly to A&E. You can read more about what an overdose on this medicine may look like on the Mounjaro overdose symptoms page, which covers each presentation in detail.

How an overdose of tirzepatide actually happens

Most overdose incidents in clinical practice follow one of a small number of patterns, and our guide to whether you can overdose on Mounjaro walks through each scenario in plain terms. The commonest is a genuine counting error: the pre-filled KwikPen delivers four weekly doses, and it is possible to lose track of which injection you are on, particularly in the first weeks of a new pen. A second scenario involves a pen mix-up, storing a 10 mg pen alongside a 5 mg pen and reaching for the wrong one. A third is a "double injection" mistake, where someone injects and then, uncertain whether the pen fired correctly, injects again.

Storage routine matters more than most people expect. Keeping your pen somewhere consistent (the fridge door shelf is a common choice) and marking the date of each injection on a calendar or in a phone note removes most of the ambiguity. If you are not sure whether you injected, the safest assumption is that you did, and the missed-dose guidance in your Patient Information Leaflet then applies. The leaflet is also the definitive reference for what to do if you accidentally use a dose at the wrong time or in the wrong amount; never rely on informal sources for this.

Dose errors are also more likely during titration, when the prescriber moves you from one strength to the next. Understanding exactly which pen to use and when is part of the clinical oversight that comes with a properly supervised prescription. At our pharmacy, every repeat order is reviewed by a prescriber before dispatch (not rubber-stamped) to confirm the dose is appropriate and to catch any concerns before a pen reaches you.

Symptoms to take seriously, and when to call for help

The NHS medicines page for tirzepatide advises contacting a doctor or going to A&E if you inject more than your prescribed dose. That guidance holds even if, immediately after, you feel fine. Some effects (particularly hypoglycaemia in patients taking concurrent diabetes medicines) can build over time rather than appear instantly.

Symptoms that warrant an immediate emergency call or A&E visit include: persistent vomiting that prevents you keeping fluids down, signs of low blood sugar (trembling, sweating, confusion, rapid heartbeat), severe stomach pain that radiates to the back (which may indicate pancreatic involvement), chest pain or palpitations, or loss of consciousness. Do not try to manage these at home.

The Yellow Card scheme run by the MHRA is the UK's mechanism for reporting suspected adverse drug reactions, including dose errors and their effects. Reporting via yellowcard.mhra.gov.uk contributes to the ongoing post-market safety monitoring of tirzepatide, the medicine carries a Black Triangle (▼) designation, meaning it is under additional MHRA surveillance. A report does not replace medical attention; it complements it.

Staying safe on a correctly prescribed course

The best protection against a tirzepatide overdose is a prescription that has been thoroughly reviewed at every stage. That means a prescriber who knows your starting weight, your medical history, and any other medicines you take before the first pen is dispensed. It also means clinical re-review before every dose increase, so the move from one strength to the next happens only when the evidence supports it, something our page on tirzepatide dosing levels explains in more detail.

Tirzepatide is not a medicine to self-source or self-titrate. The MHRA has warned publicly about counterfeit pens sold online, and a fake pen of unknown content carries risks that go well beyond a dosing error on a genuine product. Buying through a verified route with a real prescription is the baseline for safety, not a premium option.

If you are considering treatment for weight management and want to understand whether tirzepatide is clinically appropriate for you, our prescribers review every consultation the same day it is submitted. You can also read a broader overview of tirzepatide for weight loss, or if you are weighing up the relationship between the brand and the molecule, our page comparing Mounjaro and tirzepatide sets out what you need to know, or explore the full range of weight-loss treatment options before you decide. When you are ready, check your eligibility with a free consultation, a clinician, not an algorithm, will read your answers.